154,467 Shares in Immunome, Inc. (NASDAQ:IMNM) Acquired by Two Sigma Investments LP

Two Sigma Investments LP purchased a new stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 154,467 shares of the company's stock, valued at approximately $1,640,000. Two Sigma Investments LP owned approximately 0.19% of Immunome at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Sequoia Financial Advisors LLC lifted its holdings in Immunome by 11.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company's stock valued at $202,000 after acquiring an additional 2,000 shares during the period. Intech Investment Management LLC increased its holdings in shares of Immunome by 26.5% in the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company's stock valued at $201,000 after purchasing an additional 3,974 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Immunome by 3.5% in the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock valued at $1,546,000 after purchasing an additional 4,874 shares during the period. MetLife Investment Management LLC grew its position in Immunome by 17.7% during the fourth quarter. MetLife Investment Management LLC now owns 35,619 shares of the company's stock worth $378,000 after buying an additional 5,354 shares during the period. Finally, BNP Paribas Financial Markets purchased a new position in Immunome in the fourth quarter valued at about $70,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall bought 137,100 shares of the firm's stock in a transaction that occurred on Wednesday, March 26th. The shares were purchased at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the transaction, the chief executive officer now owns 806,736 shares in the company, valued at $5,881,105.44. The trade was a 20.47% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jean Jacques Bienaime purchased 5,000 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was acquired at an average price of $9.38 per share, with a total value of $46,900.00. Following the completion of the acquisition, the director now directly owns 36,415 shares in the company, valued at $341,572.70. The trade was a 15.92% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 161,400 shares of company stock worth $1,207,395 over the last ninety days. 8.60% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on IMNM shares. Wedbush reissued an "outperform" rating and set a $21.00 price target (down previously from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. Guggenheim decreased their target price on Immunome from $35.00 to $25.00 and set a "buy" rating on the stock in a research report on Thursday, March 20th. Stephens restated an "overweight" rating and issued a $30.00 price target on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital began coverage on Immunome in a research note on Tuesday, March 11th. They set an "outperform" rating and a $20.00 price target for the company. Finally, Lake Street Capital began coverage on shares of Immunome in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $23.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Immunome currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.33.

Immunome Trading Up 0.1%

Shares of NASDAQ IMNM traded up $0.01 during trading on Friday, reaching $9.13. The company had a trading volume of 1,228,054 shares, compared to its average volume of 918,306. Immunome, Inc. has a twelve month low of $5.15 and a twelve month high of $16.81. The stock has a 50-day moving average price of $7.88 and a two-hundred day moving average price of $9.50. The stock has a market capitalization of $794.42 million, a PE ratio of -1.13 and a beta of 1.94.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.14. The firm had revenue of $2.93 million during the quarter, compared to the consensus estimate of $0.46 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. On average, sell-side analysts predict that Immunome, Inc. will post -2.21 EPS for the current year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.